| NAV | $9.88 | Daily Change | -$0.13 | -1.30% |
| Market Price | $9.89 | Daily Change | -$0.11 | -1.10% |
Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1
Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 47% compound annual growth rate from 2022-2028.2
GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, Nov 2023
| Inception Date | 04/05/19 |
| Total Expense Ratio | 0.50% |
| Net Assets | $90.14 million |
| NAV | $9.88 |
| Fact Sheet | View the document |
The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
| Ticker | GNOM |
| Bloomberg Index Ticker | SOLGNOM |
| CUSIP | 37954Y434 |
| ISIN | US37954Y4347 |
| Primary Exchange | Nasdaq |
| Shares Outstanding | 9,120,000 |
| Number of Holdings | 41 |
| 30-Day Median Bid-Ask Spread | 0.18% |
| 30-Day SEC Yield | -0.21% |
| Distribution Frequency | Semi-Annually |
| NAV | $9.88 | Daily Change | -$0.13 | -1.30% |
| Market Price | $9.89 | Daily Change | -$0.11 | -1.10% |
|
As of recent month & quarter-end (03/31/24)
As of recent month & quarter-end (03/31/24)
|
Fund NAV | Market Price | Index |
|---|---|---|---|
| 1 Year | -7.57% | -7.63% | -6.37% |
| 3 Years | -20.26% | -20.29% | -19.88% |
| Since Inception | -5.73% | -5.35% | -5.25% |
| 1 Year | -7.57% | -7.63% | -6.37% |
| 3 Years | -20.26% | -20.29% | -19.88% |
| Since Inception | -5.73% | -5.35% | -5.25% |
| Year-to-Date | -1.82% | -1.56% | -1.55% |
| 1 Month | -5.41% | -5.01% | -5.23% |
| 3 Months | -1.82% | -1.56% | -1.55% |
| Since Inception | -25.53% | -24.01% | -23.62% |
| Year-to-Date | -1.82% | -1.56% | -1.55% |
| 1 Month | -5.41% | -5.01% | -5.23% |
| 3 Months | -1.82% | -1.56% | -1.55% |
| Since Inception | -25.53% | -24.01% | -23.62% |
Performance is shown on a total return basis (i.e., with gross income reinvested, where applicable). Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period.
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated.
| Net Assets (%) | Ticker | Name | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|
| 8.21 | NTRA | NATERA INC | BYQRG48 | 90.33 | 81,882 | 7,396,401.06 |
| 5.16 | CRSP | CRISPR THERAPEUTICS AG | BDHF4K6 | 55.56 | 83,719 | 4,651,427.64 |
| 4.90 | MRNA | MODERNA INC | BGSXTS3 | 103.44 | 42,736 | 4,420,611.84 |
| 4.89 | RARE | ULTRAGENYX PHARM | BJ62Z18 | 44.11 | 99,930 | 4,407,912.30 |
| 4.74 | A | AGILENT TECHNOLOGIES INC | 2520153 | 134.55 | 31,735 | 4,269,944.25 |
| 4.02 | BMRN | BIOMARIN PHARMAC | 2437071 | 90.47 | 40,068 | 3,624,951.96 |
| 3.99 | SRPT | SAREPTA THERAPEUTICS INC | B8DPDT7 | 117.89 | 30,542 | 3,600,596.38 |
| 3.77 | ILMN | ILLUMINA INC | 2613990 | 118.29 | 28,748 | 3,400,600.92 |
| 3.76 | QGEN | QIAGEN N.V. | BMGBZP0 | 39.23 | 86,310 | 3,385,941.30 |
| 3.73 | TECH | BIO-TECHNE CORP | BSHZ3Q0 | 62.73 | 53,542 | 3,358,689.66 |
| 3.59 | RCKT | ROCKET PHARMACEU | BDFKQ07 | 23.68 | 136,777 | 3,238,879.36 |
| 3.42 | ARWR | ARROWHEAD PHARMA | BYQBFJ8 | 22.53 | 136,639 | 3,078,476.67 |
| 3.41 | RNA | AVIDITY BIOSCIENCES INC | BMWHPY1 | 23.55 | 130,510 | 3,073,510.50 |
| 3.31 | ALNY | ALNYLAM PHARMACE | B00FWN1 | 145.32 | 20,533 | 2,983,855.56 |
| 3.30 | BEAM | BEAM THERAPEUTICS INC | BK6L288 | 24.31 | 122,525 | 2,978,582.75 |
| 3.30 | BNTX | BIONTECH SE-ADR | BK6H543 | 86.40 | 34,451 | 2,976,566.40 |
| 3.21 | NTLA | INTELLIA THERAPEUTICS INC | BYZM6C2 | 21.50 | 134,554 | 2,892,911.00 |
| 2.99 | MYGN | MYRIAD GENETICS INC | 2614153 | 18.64 | 144,435 | 2,692,268.40 |
| 2.86 | TXG | 10X GENOMICS INC-CLASS A | BKS3RS7 | 29.16 | 88,496 | 2,580,543.36 |
| 2.77 | LEGN | LEGEND BIOTECH CORP-ADR | BMX9K07 | 48.83 | 51,201 | 2,500,144.83 |
| 2.76 | VCYT | VERACYTE INC | BFTWZY0 | 18.86 | 131,884 | 2,487,332.24 |
| 2.11 | 1548 HK | GENSCRIPT BIOTECH CORP | BD9Q2J2 | 1.47 | 1,292,618 | 1,898,129.59 |
| 1.97 | VRTX | VERTEX PHARM | 2931034 | 393.10 | 4,521 | 1,777,205.10 |
| 1.66 | SANA | SANA BIOTECHNOLOGY INC | BMFJJ97 | 8.26 | 180,788 | 1,493,308.88 |
| 1.55 | GILD | GILEAD SCIENCES INC | 2369174 | 66.93 | 20,868 | 1,396,695.24 |
| 1.46 | VIR | VIR BIOTECHNOLOGY INC | BK4PZ38 | 8.25 | 159,971 | 1,319,760.75 |
| 1.38 | RGNX | REGENXBIO INC | BZ0G875 | 17.03 | 72,884 | 1,241,214.52 |
| 0.92 | EDIT | EDITAS MEDICINE INC | BZ8FPH3 | 5.61 | 148,388 | 832,456.68 |
| 0.87 | CDNA | CAREDX INC | BP3YM74 | 8.28 | 94,998 | 786,583.44 |
| 0.78 | FLGT | FULGENT GENETICS INC | BYQBFQ5 | 20.09 | 34,821 | 699,553.89 |
| 0.76 | ALLO | ALLOGENE THERAPEUTICS INC | BFZNYB7 | 3.51 | 194,980 | 684,379.80 |
| 0.69 | PACB | PACIFIC BIOSCIEN | B4N8MH9 | 1.40 | 444,456 | 622,238.40 |
| 0.61 | CRBU | CARIBOU BIOSCIENCES INC | BNYJR68 | 3.91 | 139,370 | 544,936.70 |
| 0.59 | VERV | VERVE THERAPEUTICS INC | BNKGXX2 | 6.74 | 78,511 | 529,164.14 |
| 0.59 | LYEL | LYELL IMMUNOPHARMA INC | BN6MB18 | 2.38 | 221,596 | 527,398.48 |
| 0.58 | 4974 JP | TAKARA BIO INC | B03ML21 | 6.20 | 84,210 | 522,177.69 |
| 0.46 | TSVT | 2SEVENTY BIO INC | BMTXV88 | 5.06 | 81,812 | 413,968.72 |
| 0.40 | QURE | UNIQURE NV | BJFSR88 | 4.67 | 77,457 | 361,724.19 |
| 0.27 | PSTX | POSEIDA THERAPEUTICS INC | BJ4SF41 | 2.04 | 117,170 | 239,026.80 |
| 0.20 | BLUE | BLUEBIRD BIO INC | BBFL7S1 | 0.96 | 189,865 | 182,896.95 |
| 0.07 | E | SCILEX HOLDING RESTRICTED | 9A80I96 | 0.29 | 226,071 | 66,125.64 |
| 0.01 | CASH | 1.00 | 10,046 | 10,045.98 | ||
| 0.00 | JAPANESE YEN | 0.01 | -1 | -0.01 | ||
| -0.01 | OTHER PAYABLE & RECEIVABLES | 1.00 | -7,387 | -7,387.09 |
| Industry | Weight (%) | |
|---|---|---|
| Biotechnology | 76.2 | |
| Medical Specialties | 10.6 | |
| Medical/Nursing Services | 8.7 | |
| Pharmaceuticals: Major | 3.8 | |
| Miscellaneous Commercial Services | 0.8 |
| Country | Weight (%) | |
|---|---|---|
| United States | 78.6 | |
| Italy | 6.9 | |
| Switzerland | 5.1 | |
| Netherlands | 3.8 | |
| Germany | 2.9 | |
| China | 2.3 | |
| Japan | 0.5 |
All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.
Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified.
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.
Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.
Carefully consider the Fund’s investment objectives, risks, and charges and expenses before investing. This and other information can be found in the Fund’s summary or full prospectuses. Please read the prospectus carefully before investing.
Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.